Inozyme Pharma, Inc.

Inozyme Pharma engages in the research and development of novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Its lead product candidate is INZ-701, which is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial -

Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency (PXE) –

Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023

- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at virtual event on Thursday, Feb. 16, 2023 –

Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress

- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more than tripling prior estimate -

Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency

BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on Thursday, December 8, 2022, from 8:00-8:30am ET.

Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference

- Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of 2022 –

Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates

- Peer-reviewed article in Human Mutation reports 3-fold increase in pathogenic/likely pathogenic ENPP1 variants –

Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference. The prerecorded presentation will become available on-demand on Monday, September 12, 2022, at 7:00 AM ET.

Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

- Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency –

Inozyme Pharma Reports Second Quarter 2022 Financial Results and Provides Business Updates

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that it has entered into a debt financing facility for up to $70 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.

Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures

Inozyme Pharma Inc (NASDAQ: INZY) has announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects in the Phase 1 portion of its ongoing Phase 1/2 trial of INZ-701 in ABCC6 Deficiency, which presents as pseudoxanthoma elasticum (PXE) in older.

Inozyme Pharma Post Encouraging Early Data From Genetic Disorder Trial

- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) –

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

The consensus price target hints at a 308.5% upside potential for Inozyme Pharma, Inc. (INZY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Inozyme Pharma, Inc. (INZY)? Wall Street Analysts Think 309%

New technology aims to expand testing to approximately 1,000 diseases and sequencing to 3.7 million newborns annually New technology aims to expand testing to approximately 1,000 diseases and sequencing to 3.7 million newborns annually

Inozyme Pharma Announces Partnership with Rady Children's Institute for Genomic Medicine to Advance Newborn Screening for Genetic Diseases

BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Kurt Gunter, M.D., as chief medical officer. Dr. Gunter, who most recently served as chief medical officer, cell therapy, and head of regulatory affairs at Athenex, brings to Inozyme over 30 years of expertise in regulatory affairs, clinical development, and government relations.

Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the Jefferies Healthcare Conference. The presentation will take place on Wednesday, June 8, 2022 at 2:30 PM ET.

Inozyme Pharma to Present at the 2022 Jefferies Healthcare Conference

– Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency –

Inozyme Pharma Reports First Quarter 2022 Financial Results and Provides Business Highlights

BOSTON, April 14, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.

Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market

Inozyme Pharma Inc (NASDAQ: INZY) has dosed the first patient in its Phase 1/2 trial of INZ-701 in adult patients with ABCC6 Deficiency. Also, the second cohort in the ongoing Phase 1/2 clinical trial in ENPP1 Deficiency has been fully enrolled.

Inozyme Pharma Starts Dosing In INZ-701 Trial For Calcification Disorders

- First patient dosed in Phase 1/2 clinical trial in ABCC6 Deficiency –

Inozyme Pharma Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency

BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13th at 8:45 AM ET.

Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference

Inozyme Pharma Inc (NASDAQ: INZY) announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in the Phase 1 portion of its Phase 1/2 trial of INZ-701 in ENPP1 Deficiency.  ENPP1 Deficiency manifests generalized arterial.

Why Inozyme Pharma Shares Are Jumping Today

- Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) levels observed in all three patients in lowest dose cohort (0.2 mg/kg) –

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

– Phase 1/2 trial of INZ-701 in adult patients with ENPP1 Deficiency underway –

Inozyme Pharma Reports Full Year 2021 Financial Results and Provides Business Highlights

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Sanjay S. Subramanian, M.S., MBA, as chief financial officer (CFO), effective as of the later of (i) March 21, 2022 and (ii) the date immediately following the date of the filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and Soojin Kim, Ph.D., as senior vice president and chief technical operations officer (CTOO). Dr. Kim succeeds Inozyme senior vice president and CTOO, Steven Jungles, who has retired from the Company.

News for Inozyme Pharma, Inc. Stock (INZY)